As per the DelveInsight, the Uncomplicated Urinary Tract Infections epidemiological analysis demonstrated that approximately 35.3 million cases in the 7MM (the US, EU5, and Japan), which is expected to rise further in the next decade.
At present, the Uncomplicated Urinary Tract Infections Market lacks the new treatment option as antibiotics are the only available treatment options to cater the need of the affected population. However, some of the key pharma players, including GSK, Iterum Therapeutics, The Janssen Pharmaceutical Companies of Johnson & Johnson, Inmunotek, Fimbrion Therapeutics, and several others in the Uncomplicated Urinary Tract Infections Therapeutics Market are exploring potential therapies with novel MoA to bridge the gaps between the medical needs and treatment.
In the coming years, the rising awareness about the disease, available therapies, and better diagnosis approaches are expected to push the growth of the uUTI therapy market.
For more details, visit: Treatment Options in the Uncomplicated Urinary Tract Infections Market